However, based on the literature, the availability of LAG-3 targets in the tumor microenvironment is expected to be rather low (0.41 ng/mg in cervical tumors) as compared to other targets, such as human epidermal growth factor receptor-2-2 (12–800 ng/mg in breast cancer) or MET (22–700 ng/mg in NSCLC) [19, 20]. This evidence concerns the gene LAG3 and neoplasm.